

COMPOSITION FOR INTRACELLULAR TRANSPORT OF BIOLOGICAL
PARTICLES OR MACROMOLECULES

5 The present invention relates to novel means for the intracellular transfer of macromolecules or particles of interest.

10 The import of macromolecules, and in particular of polynucleotides or proteins, into living animal cells constitutes a basic approach both for basic research and in the context of various applications, for example in gene therapy.

15 One of the major difficulties of this approach results from the need to transport these macromolecules across the cell membrane.

20 This problem has been the subject of numerous research studies which have resulted in the development of various methods of intracellular transfer and of various types of vector.

25 Thus, the introduction of polynucleotides into cells is currently based mainly on techniques of transfection (calcium phosphate, electroporation), of lipofection (liposomes, charged lipids) or of viral infection (lentivirus, adenovirus, herpesvirus and the like) or on the use of nanoparticles.

30 More recently, it has been proposed to use transducing peptides. This term denotes peptides comprising, or consisting of, a sequence called "transduction domain" which confers on them the capacity to penetrate inside
35 a living cell independently of the presence of specific transporters or receptors.

Review articles relating to transducing peptides have been recently published by LIDGREN et al., TiPS, 21,

99-102, (2000); SCHWARZE and DOWDY *TIPS*, 21, 45-48, (2000); SCHWARZE et al. *Trends Cell. Biol.*, 10, 290-295, (2000); PROCHIANTZ *Current Opinion in Cell Biology*, 12, 400-406, (2000); Cell-Penetrating
5 Peptides. Processes and applications. Ed. Ulo Langel. CRC Press (2002).

As examples of transducing peptides, there may be mentioned in particular:

- 10 - penetratins, which are peptides derived from the third helix of a homeodomain; peptides of the penetratin family are described for example in the publications by JOLIOT et al., *Proc. Natl. Acad. Sci. USA*, 88, 1864-1868, (1991); DEROSI et al.,
15 *J. Biol. Chem.*, 269, 14, 10444-10450, (1994); BRUGIDOU et al. *Biophys. Biochem. Res. Com.*, 214, 685-693, (1995), and in patent US 5888762, patent US 6080724, or PCT application WO 00/01417;
- peptides derived from the HIV1 Tat protein, and in
20 particular from fragment 48-60 of said protein; such peptides are described for example by FAWELL et al. *Proc. Natl. Acad. Sci. USA*, 91, 664-668, (1994) or by VIVES et al. *J. Biol. Chem.*, 272, 16010-16017, (1997);
- 25 - peptides derived from the HSV VP22 protein; such peptides are described for example by ELLIOTT and O'HARE *Cell*, 88, 223-233, (1997);
- peptides derived from a signal sequence conjugated with a nuclear localization sequence; such
30 peptides are described for example by LIN et al. *J. Biol. Chem.*, 270, 14255-14258, (1995); *J. Biol. Chem.*, 271, 5305-5308, (1996), LIU et al. *Proc. Natl. Acad. Sci. USA*, 93, 11819-11824, (1996), MORRIS et al. *Nucleic Acids Res.*, 25, 2730-2736,
35 (1997), CHALOIN et al. *Biochemistry*, 36, 11179-11187, (1997); *Biochem. Biophys. Res. Commun.*, 243, 601-608, (1998), ZHANG et al. *Proc. Natl. Acad. Sci. USA*, 95, 9184-9189, (1998);
- transportans which are derived from a fusion

between a portion of a neuropeptide, galanin, and a wasp venom peptide; POOGA et al., FASEB J., 12, 67-77, (1998) ; Ann. New York Acad. Sci., 863, 450-453, (1998).

5

The transducing peptides may import into living cells, in particular animal cells, molecules or molecular complexes of a diverse nature (nucleic acids, proteins, peptides/nucleic acids, nucleotide analogs, liposomes).

10

These molecules or molecular complexes are usually designated under the general term of "cargos".

15

It has been reported that some transducing peptides can import cargos of a large size.

20

Thus, LEWIN et al. (Nat. Biotech, 18, 410-414, 2000) conjugated a derivative of the transducent peptide TAT 48-60 with nanoparticles consisting of an iron oxide core coated with a dextran envelope, and observed that the nanoparticles thus modified (having a diameter of 45 nm) were imported into living cells.

25

EGUCHI et al. (J. Biol. Chem., 276, 28, 26204-26210, 2001) constructed recombinant λ phages expressing, at their surface, a chimeric protein comprising the transducing peptide TAT fused with the N-terminal end of the D protein of the phage, and containing a marker gene. They observed, after incubating these phages with COS-1 cells in culture, an intracellular expression of the marker gene in a proportion of these cells which could be up to 30%.

30

35

It is however generally considered that one of the major limitations of the transducing peptides mentioned above, such as penetratins or TAT peptides, lies in the need to couple the transducing peptide and the cargo by (a) covalent bond(s).

With the aim of dispensing with this limitation, peptides designed to bind through ionic or hydrophobic interactions either to nucleic acids or to proteins have been constructed. One of these peptides, called
5 MPG, is intended for the intracellular transport of nucleic acids (MORRIS et al., Nucl. Acids Res., 2730-2736, 1997; Nucl. Acids Res., 3510-3517, 1999); it comprises two distinct regions, separated by a linking peptide: an N-terminal hydrophobic region derived from
10 the signal sequence rich in glycine of the gp41 protein of HIV1, which allows fusion with the cell membrane, and a hydrophilic region derived from the nuclear localization sequence of the SV40 T antigen, which allows interaction of the peptide with the nucleic
15 acid, and its nuclear targeting.

The other, called Pep-1 (MORRIS et al., Nature Biotech, 19, 1173-1176, 2001) is intended for the transport of proteins. It differs from MPG by the nature of the N-
20 terminal hydrophobic region, which consists of a sequence rich in tryptophan, intended to allow targeting to the cell membrane and the formation of hydrophobic interactions with the proteins.

25 These two types of peptide are also described in PCT application WO 02/10201, which proposes, in a general manner, to use, in order to import proteins into living cells, peptides of 16 to 30 amino acids comprising two distinct successive domains: a hydrophobic domain
30 containing 3 to 5 tryptophan residues including at least one Trp-Trp pair, alternating with glutamic acid and threonine residues; a hydrophilic domain containing 4 or 5 consecutive basic residues (lysine or arginine), these two domains being possibly separated by a spacer
35 domain containing a proline residue or a glutamine residue. An effective import was however observed only in the case of peptides additionally bearing a cysteamine group.

Moreover, in the context of the work on the properties of transducing peptides of the penetratin family, the inventors evaluated the capacity of these peptides to import cargos of a large size. With this aim in mind, they tested one of these peptides using a λ phage as cargo. They then observed not only that this peptide was capable of importing the phage into an animal cell, but also that, contrary to what was assumed or wanted now, the import could take place without the need to couple the peptide and the phage by a covalent bond. In addition, the inventors observed that the efficacy of this import was much higher than that observed by EGUCHI et al. with the transducing peptide TAT coupled by a peptide bond to the N-terminal end of the λ phage D protein.

To explain these results, which are surprising in the light of the structural difference between the penetratins and the peptides of the PCT application WO 02/10201, the inventors propose the following hypothesis: penetratins have a transduction domain capable of adopting an amphiphilic secondary structure (in the form of an α helix or in the form of a β sheet) possessing a surface having hydrophobic residues, and a charged surface comprising a tryptophan residue flanked by 2 basic residues bringing about the interaction with the membranes and the formation of a reverse micelle allowing internalization of the peptide in the cell. For example, in the case of the penetratin-type pANTP, the Ile, Trp and Phe residues at positions 3, 14, and 7 of the peptide sequence form a hydrophobic triplet in the α helix; this hydrophobic triplet is distant from the charged zone consisting of the Lys residue (position 13 of the peptide sequence) and Arg residue (position 10 of the peptide sequence), which, in the α helix, flank the Trp residue at position 6 of the peptide sequence (DEROSSI et al. J. Biol. Chem, 271, p. 18188-18193, 1996).

It is assumed that the hydrophobic surface of the transduction domain allows the formation of interactions of sufficient strength to bring about a stable attachment of the transducing peptide to the cargo. The interaction with the membrane is thought to occur through the charged surface of the transduction domain; the Trp flanked by two charged amino acids can insert itself into the membrane, (this insertion was observed by fluorescence studies of tryptophan), destabilizing it and allowing the passage of the vector and its cargo.

The subject of the present invention is a method for preparing a composition which makes it possible to introduce into a living cell, and in particular a eukaryotic cell, and especially an animal cell, a cargo consisting of a macromolecule or a molecular assembly (for example a particle), having a size of less than or equal to about 1 μm along its largest dimension, said cargo having one or more hydrophobic domains at its surface, said method is characterized in that it comprises the adsorption, onto said hydrophobic domain(s), of at least one transducing peptide, with the exception of the peptides described in PCT application WO 02/10201.

According to a preferred embodiment of the present invention, said cargo is a protein or a particle having a surface of a proteic nature.

It is also possible to use, as cargo, liposomes, nanoparticles, glycolipids or any other natural or artificial macromolecular combination.


According to another preferred embodiment of the present invention, said cargo generally has a size of less than or equal to 500 nm along its largest dimension.

This includes for example viral or pseudoviral particles, in particular phage particles.

5 According to yet another preferred embodiment of the present invention, said transducing peptide is a peptide of the penetratin family.

10 The term "peptide of the penetratin family" is defined here as any peptide comprising a transduction domain capable of adopting an amphiphilic secondary structure (in the form of an α helix or in the form of a β sheet) which has a surface comprising hydrophobic residues allowing interaction with the cargo, and a surface allowing interaction with the membranes, comprising a
15 tryptophan residue flanked by basic residues.

This includes in particular the penetratins described in PCT application WO 00/01417, and more particularly those comprising a transduction domain defined by one
20 of the formulae below:



25 in which X_6 represents a tryptophan residue, X_1 , X_2 , X_4 , X_9 , X_{15} , X_{16} , are nonhydrophobic amino acids, and X_3 , X_7 , and X_{14} are hydrophobic amino acids.

30 Particularly preferred transduction domains for carrying out the present invention are those in which X_{10} and X_{13} are basic amino acids.

It is also possible to use penetratin derivatives, for example certain truncated or substituted penetratins
35 described in PCT application WO 00/01417, or PCT application WO 00/29427.

It is also possible to use a transducing peptide comprising, in addition to the transduction domain, one

or more other functional domains; by way of example, there may be mentioned peptides comprising a transduction domain and a nuclear export sequence which are described in PCT application WO 02/39947.

5

The adsorption of the transducing peptide takes place in a simple manner, by incubating said transducing peptide with the cargo for at least 15 minutes, preferably for 30 to 60 minutes.

10

The incubation can take place *ex vivo* or *in vivo*, in a very broad temperature range generally between 15 and 40°C. The procedure will be preferably carried out at room temperature, that is to say in the region of 20 to 25°C, or at physiological temperatures (in the region of 37°C), in a medium at neutral pH; this may be for example a cell culture medium, or an NaCl solution (9 g/l).

15

20 The transducing peptide/cargo molar ratio in the incubation medium depends in particular on the size of the cargo; for example, in the case of a bacteriophage, it is possible to use a molar ratio corresponding to 1000 to 500 000 molecules of peptide per bacteriophage.

25

The subject of the present invention is also a composition comprising a cargo at the surface of which a transducing peptide capable of being obtained by the method in accordance with the invention is adsorbed.

30

The compositions in accordance with the invention may be used immediately after their preparation; where appropriate, they may also be stored for at least three days in the incubation medium, at temperatures of 35 between 4°C and 37°C approximately.

The subject of the present invention is also the use of compositions in accordance with the invention for introducing a cargo, as defined above, into a living

cell.

In particular, the subject of the present invention is thus a method for introducing a cargo into a living
5 cell, characterized in that it comprises bringing said cell into contact with a composition in accordance with the invention comprising said cargo.

The method in accordance with the invention may be
10 performed on cells in culture, by adding to the culture a composition in accordance with the invention, and incubating for 1 to 14 hours, preferably for 2 to 6 hours.

15 Preferably, the composition in accordance with the invention is used in an amount of 10 000 to 20 000 cargo/transducing peptide complexes per cell.

The method in accordance with the invention may also be
20 performed *in vivo*, for example by injecting a composition in accordance with the invention into an animal.

The subject of the present invention is also the use of
25 a composition in accordance with the invention for producing a medicament, and in particular as a vector for an active ingredient consisting of the cargo or contained therein.

30 The present invention has the advantage of allowing the introduction into living cells of any hydrophobic cargo or any cargo whose surface has at least one hydrophobic domain, without the need to perform preliminary coupling by a covalent bond between the cargo and the
35 transducing peptide. The present invention has a very special advantage for introducing, into living cells, viral or pseudoviral particles, in particular bacteriophages, containing polynucleotides of interest which it is desired to express in said cells.

These particles may thus be used for example as vectors for gene therapy *in vivo* or *ex vivo*. It may also be possible to prepare compositions in accordance with the invention from phage libraries containing polynucleotides encoding various polypeptides capable of modifying the behavior of certain cells (migration, proliferation, differentiation and the like), and to use these compositions to cause these phage libraries to enter into tissues, in culture or *in vivo*, and to identify sequences regulating these behaviors.

The present invention will be understood more clearly with the aid of the additional description which follows, which refers to nonlimiting examples illustrating the use of the present invention to introduce phages into living cells.

EXAMPLE 1: ADSORPTION OF A TRANSDUCING PEPTIDE ONTO LAMDA BACTERIOPHAGES

Preparation of the phages:

The gene for the autofluorescent protein EGFP (CLONTECH) or that for the homeoprotein En2 (Engrailed2) from chicken (LOGAN et al., 1992, Dev Genetics 13: 345-358) were placed under the control of the CMV promoter and upstream of the SV40 polyadenylation sequence, in a plasmid derived from pBK-CMV (STRATAGENE) possessing a unique EcoRI site upstream of the CMV promoter, and a unique SalI site downstream of the polyadenylation signal.

The functionality of these constructs was verified by electroporation and transient expression in COS cells, and detection of the autofluorescence of GFP or immunocytochemical detection of the Engrailed 2 protein with the aid of a polyclonal antibody directed against

this protein (gift from Dr S. SAULE, UMR 146, Institut Curie, Orsay)).

The fragment flanked by the two unique sites (EcoRI and
5 SalI) was then transferred into the genome of the
Lambda-ZAP phage (STRATAGENE), between the EcoRI and
XhoI sites, and the recombinant DNA was encapsidated in
vitro with the aid of the GIGAPACK PLUS reagents
(STRATAGENE). The resulting phages (called Lambda-ZAP-
10 GFP and Lambda-ZAP-En2 respectively) allowed the
infection of competent bacteria (XL1Blue-MRF' strain,
STRATAGENE), and their titer was then determined and
they were stored after a first round of amplification.
To check the quality of the recombinants obtained, the
15 phagemids within the genomes of the recombinant Lambda
phages were automatically excised by co-infection of
XL1Blue-MRF' bacteria with a helper phage (ExAssist,
STRATAGENE). After culturing in liquid medium, the
bacteria which were still alive and the Lambda virions
20 were destroyed by heating, and the recombinant
filamentous phages are recovered. The plasmid forms of
these recombinant phagemids are recovered after
infection of nonpermissive bacteria for the replication
of the filamentous phage (SOLR strain, STRATAGENE), and
25 the functional integrity of these excised plasmids is
verified by electroporation in COS cells. After this
verification, the recombinant lambda phages are
amplified in order to reach a titer of at least 10^{11}
particles per ml, and then concentrated using PEG,
30 dialyzed against PBS supplemented with Ca^{++} and Mg^{++} , and
stored at 4°C.

Adsorption of the transducing peptide:

35 The transducing peptide used is a penetratin having the
sequence:

RQIKIWFQNRRMKWKK (SEQ ID NO:1)

corresponding to helix 3 of the pAntp peptide (homeodomain of the Drosophila Antennapedia protein).

5 The biotinylated penetratin is mixed with the recombinant phages in an amount of 10 μ g of peptide per 10^9 phage particles, in 50 to 100 μ l of appropriate medium (DMEM/F12 medium (1:1) or PBS-Dulbecco medium). The mixture is incubated at room temperature for 30 min.

10

EXAMPLE 2: INTRODUCTION OF PHAGES INTO CELLS IN CULTURE

The cells used are dog kidney epithelial cells (MDCK).

15 The phages used are labeled with the fluorochrome Cy3 (AMERSHAM) by covalent bonding of the fluorochrome to the capsid proteins, according to the manufacturer's instructions. They are then incubated in the presence of penetratin, as described in Example 1 above. As
20 negative control, phages labeled with the fluorochrome Cy3 are used, which are incubated under the same conditions in the absence of penetratin.

The phage/penetratin preparation, or the control
25 preparation is added to the culture or cell suspension medium (depending on whether the treated cells have already been inoculated or whether they have just been dissociated) in an amount of 10 000 phages/cell, and left in contact with the cells for 4 hours.

30

The cells are then washed and resuspended in fresh medium, and then fixed in 4% paraformaldehyde in PBS for 10 min at room temperature, rinsed in PBS and mounted in mounting medium for fluorescent specimens
35 DAKO containing 1 μ g/ml of DAPI (4'-6-diamidino-2-phenylindole). They are then observed under a Leica TCS type epifluorescence confocal microscope. The images

are analyzed and processed with the aid of the Adobe Photoshop software.

The results are illustrated in figure 1:

5 Figure 1A: control preparation with phage without penetratin.

Figure 1B: phage/penetratin preparation.

10 A high intracellular fluorescence is observed in the cells which received the phage/penetratin preparation. On the other hand, in the case of the cells which received only the phage preparation, no fluorescence is observed.

15

EXAMPLE 3: INTRODUCTION OF LAMBDA PHAGES IN VIVO INTO MOUSE BRAIN CELLS

20 Various phage/penetratin preparations (recombinant phages expressing GFP; recombinant phages expressing En2; phages labeled with the fluorochrome Cy3) are administered to adult mice by infusion into the lateral ventricle of the brain.

25 On D-1 before the infusion, the phages (solution at 6.5×10^8 pfu/ μ l) are dialyzed against 0.9% NaCl containing 10 mM of $MgCl_2$ (for the stability of the phage) at 4°C overnight. On the day of the infusion, the phage/penetratin mixture is prepared: 70 μ l of the
30 solution of phages dialyzed against 0.9% NaCl (that is 6.5×10^{10} pfu) + 3 μ l of 9% NaCl + 27 μ l of the penetratin stock solution (that is 162 μ g), that is about 5×10^5 molecules of penetratin per phage particle. 100 μ l of mixture are loaded into an osmotic
35 micropump (ALZET 1003D) collected by a catheter to a cannula which will be implanted into the lateral ventricle. The whole micropump is immersed in 0.9% NaCl at 37°C for 4 hours in order to initiate its rate of flow.

The pumps are placed in a subcutaneous pouch at the level of the scapular region of the animal, and the canula is implanted into the lateral ventricle of the brain according to the following stereotaxic coordinates: lateral 0.8 mm, anteroposterior 0 mm, dorsoventral 2 mm relative to the Bregma of the skull taken as origin of the coordinates.

The infusion is performed for three days at a flow rate of 1 μ l/hour. The infused animals are then humanely killed by anesthesia followed by intracardiac infusion of 4% paraformaldehyde in PBS; the brains are removed and post-fixed overnight at 4°C in this fixative. The next day, they are cut using a vibratome into frontal sections 50 μ m thick.

The sections are either observed immediately after mounting in mounting medium (DAKO+DAPI) in the case of direct fluorescence (GFP or CY3), or used for the immunodetection of the heterologous protein expressed by the phage (in the case of the phage expressing GFP or En2). The penetratin is detected by a streptavidin coupled to the fluorochrome Cy3 (IMMUNOTECH).

For the immunodetection, and/or the detection of the penetratin, the sections are preincubated for about one hour in PBS buffer containing 5% FCS and 0.25% Triton X-100 (PBST) at room temperature. The antibodies are diluted in the same buffer, at 1/5000 for the anti-En2 polyclonal antibody, and at 1/500 for the anti-GFP polyclonal antibody (SANTA-CRUZ), and incubated with the sections overnight at 4°C. The sections are then rinsed 3 \times 15 min in PBS buffer; an FITC-coupled fluorescent secondary antibody to rabbit immunoglobulins (JACKSON) is then added after 1/500 dilution in PBST.

For the detection of penetratin, the fluorescent

streptavidin is diluted 1/500 in PBST.

After incubating for 1 hour at room temperature, and three 15 min rinses in PBS, the sections are mounted in
5 DAKO+DAPI medium, and observed by epifluorescence confocal microscopy.

The results are illustrated in figures 2 and 3:

10 Figures 2A and 2B represent labelings on frontal sections 50 μ m thick.

Figure 2A: Detection of Cy3 phage in cerebral
parenchyma of an adult mouse after infusion of the
15 penetratin/phage mixture into the lateral ventricle.

Figure 2B: Detection of a GFP fluorescence in the
cerebral parenchyma of an adult mouse after infusion of
the penetratin/GFP phage mixture into the lateral
20 ventricle.

Figure 3: Colocalization of the Engrailed 2 protein and
of penetratin in the cerebral parenchyma of an adult
mouse after infusion of the penetratin/phage encoding
25 En 2 mixture.

Figure 3A: Immunodetection of the Engrailed 2 protein
encoded by the phage.

30 Figure 3B: detection on the same section of penetratin
with the aid of fluorescent streptavidin.

Figures 3D and 3E are magnifications of figures 3A and
3B respectively.